Article Versions Notes

Gothland A, Leducq V, Grange P, Faye O, Beauvais Remigereau L, Sayon S, Désiré N, Jary A, Laplantine E, Maiga AI, et al. Primaquine as a Candidate for HHV-8-Associated Primary Effusion Lymphoma and Kaposi’s Sarcoma Treatment. Cancers. 2022; 14(3):543. https://doi.org/10.3390/cancers14030543

Gothland, Adélie, Valentin Leducq, Philippe Grange, Ousmane Faye, Laurianne Beauvais Remigereau, Sophie Sayon, Nathalie Désiré, Aude Jary, Emmanuel Laplantine, Almoustapha Issiaka Maiga, and et al. 2022. "Primaquine as a Candidate for HHV-8-Associated Primary Effusion Lymphoma and Kaposi’s Sarcoma Treatment" Cancers 14, no. 3: 543. https://doi.org/10.3390/cancers14030543

Gothland, A., Leducq, V., Grange, P., Faye, O., Beauvais Remigereau, L., Sayon, S., Désiré, N., Jary, A., Laplantine, E., Maiga, A. I., Dupin, N., Marcelin, A.-G., & Calvez, V. (2022). Primaquine as a Candidate for HHV-8-Associated Primary Effusion Lymphoma and Kaposi’s Sarcoma Treatment. Cancers, 14(3), 543. https://doi.org/10.3390/cancers14030543